TY - JOUR
T1 - Electroporation of epicardial autonomic ganglia
T2 - Safety and efficacy in medium-term canine models
AU - Padmanabhan, Deepak
AU - Naksuk, Niyada
AU - Killu, Ammar K.
AU - Kapa, Suraj
AU - Witt, Chance
AU - Sugrue, Alan
AU - Desimon, Christopher V.
AU - Madhavan, Malini
AU - de Groot, J. R.
AU - O'Brien, Barry
AU - Rabbette, Tadhg
AU - Coffey, Kenneth
AU - Asirvatham, Samuel J.
N1 - Funding Information:
The authors thank Jennifer Mears for her contributions in preparing this manuscript. Research reported in this publication was supported by Commercialization Fund Programme (Enterprise Ireland) and the Minnesota Partnership for Biotechnology and Medical Genomics (University of Minnesota and Mayo Clinic). Mayo Clinic has filed a patent application for this technology and named Drs Samuel J. Asirvatham and K. L. Venkatachalam as inventors. This patent application has not been licensed, and neither Mayo Clinic nor the inventors have received any financial benefits for the patent filing to date. This study has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. Other authors: No disclosures.
Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019/4
Y1 - 2019/4
N2 - Background: Endocardial radiofrequency ablation of epicardial ganglionic plexus (GP) for atrial fibrillation (AF) is complicated by myocardial damage. Objectives: We hypothesized that an epicardial approach with a novel nitinol catheter system capable of causing irreversible electroporation (IRE) with direct current (DC) could selectively and permanently destroy GP without collateral myocardial injury. Methods: Acute studies and medium-term terminal studies (mean survival, 1137 days) were performed with seven dogs. In the acute studies, DC was used to target epicardial GP within the transverse sinus, oblique sinus, vein of Marshall, and right periaortic space. Successful electroporation was defined as the presence of ablative lesions in the GP without collateral myocardial damage. A four-point integer system was used to classify histologic changes in tissue harvested from the ablation sites. Atrial effective refractory period (AERP) was measured during the acute and medium-term studies. Results: For six dogs in the medium-term studies, the postablation period was uneventful without complications. Lesions were successfully created at 20 of 21 sites (95.2%) with more than minimal myocardial damage in one dog. An increase in AERP occurred in both atria during the acute studies but was maintained only in the right atrium at medium-term follow-up (5032 milliseconds). No dog had damage to the esophagus, adjacent great arteries, or pulmonary veins. Conclusions: This proof-of-concept study suggests that safe, effective, and selective epicardial ablation of GP can be performed with DC by IRE with minimal collateral myocardial damage.
AB - Background: Endocardial radiofrequency ablation of epicardial ganglionic plexus (GP) for atrial fibrillation (AF) is complicated by myocardial damage. Objectives: We hypothesized that an epicardial approach with a novel nitinol catheter system capable of causing irreversible electroporation (IRE) with direct current (DC) could selectively and permanently destroy GP without collateral myocardial injury. Methods: Acute studies and medium-term terminal studies (mean survival, 1137 days) were performed with seven dogs. In the acute studies, DC was used to target epicardial GP within the transverse sinus, oblique sinus, vein of Marshall, and right periaortic space. Successful electroporation was defined as the presence of ablative lesions in the GP without collateral myocardial damage. A four-point integer system was used to classify histologic changes in tissue harvested from the ablation sites. Atrial effective refractory period (AERP) was measured during the acute and medium-term studies. Results: For six dogs in the medium-term studies, the postablation period was uneventful without complications. Lesions were successfully created at 20 of 21 sites (95.2%) with more than minimal myocardial damage in one dog. An increase in AERP occurred in both atria during the acute studies but was maintained only in the right atrium at medium-term follow-up (5032 milliseconds). No dog had damage to the esophagus, adjacent great arteries, or pulmonary veins. Conclusions: This proof-of-concept study suggests that safe, effective, and selective epicardial ablation of GP can be performed with DC by IRE with minimal collateral myocardial damage.
KW - atrial fibrillation
KW - cardiac ganglionic plexus
KW - direct current ablation
KW - irreversible electroporation
KW - novel ablation catheters
UR - http://www.scopus.com/inward/record.url?scp=85061033258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061033258&partnerID=8YFLogxK
U2 - 10.1111/jce.13860
DO - 10.1111/jce.13860
M3 - Article
C2 - 30680839
AN - SCOPUS:85061033258
SN - 1045-3873
VL - 30
SP - 607
EP - 615
JO - Journal of cardiovascular electrophysiology
JF - Journal of cardiovascular electrophysiology
IS - 4
ER -